HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary methods and results All Versions of this Article: 34/1/132    most recent 09031936.00130408v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hoeper, M. M. Articles by Ewert, R. PubMed PubMed Citation Articles by Hoeper, M. M. Articles by Ewert, R.

Long-term outcome with intravenous iloprost in pulmonary arterial hypertension

¹ Dept of Respiratory Medicine, Hanover Medical School, Hanover, ² Dept of Respiratory Medicine, University of Giessen Lung Center, Giessen, ³ Dept of Respiratory Medicine, University of Leipzig, Leipzig, ⁴ Dept of Internal Medicine I, Carl-Gustav-Carus University Dresden, Dresden, ⁵ Dept of Cardiology, DRK Kliniken Berlin Köpenick, Berlin, and ⁶ Dept of Cardiology and Respiratory Medicine, University of Greifswald, Greifswald, Germany.

CORRESPONDENCE: M. M. Hoeper, Hanover Medical School, Dept of Respiratory Medicine, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. E-mail: hoeper.marius{at}mh-hannover.de

Keywords: Hypertension, iloprost, prognosis, prostanoids, pulmonary

Received: November 19, 2008
Accepted February 5, 2009

There is limited data on the long-term efficacy of intravenous iloprost in patients with pulmonary arterial hypertension (PAH).

This retrospective multicentre analysis evaluated the clinical course of patients with PAH treated with i.v. iloprost, in most cases after having received inhaled iloprost as first-line therapy.

Between 1997 and 2001, 79 PAH patients were treated with i.v. iloprost and followed until 2007. These patients had advanced and progressive disease as indicated by a mean pulmonary vascular resistance of 1,533 dyn·s·cm^–5 at the time of diagnosis and of 1,858 dyn·s·cm^–5 at the onset of i.v. iloprost therapy. Introduction of i.v. iloprost therapy resulted in initial haemodynamic and clinical improvement. At the end of the observation period, however, 50 (61%) patients had died and 21 (26%) required lung transplantation. Transplantation-free survival rates at 1, 3, and 5 yrs were 86%, 59% and 45%, respectively, after the diagnosis of PAH, and 54%, 31% and 15%, respectively, after the introduction of i.v. iloprost therapy. Predictors of an adverse outcome at baseline were a low 6-min walk distance and a low mixed venous oxygen saturation.

In conclusion, despite initial haemodynamic and clinical improvement, overall long-term survival with i.v. iloprost therapy was limited.